Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer-BOOSTER trial, a multicenter randomized phase II study
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Sep 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Anastrozole; Exemestane; Fulvestrant; Goserelin; Letrozole; Leuprorelin; Paclitaxel
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Therapeutic Use
- Acronyms BOOSTER
- Sponsors Chugai Pharmaceutical
- 31 Aug 2018 Biomarkers information updated
- 06 Mar 2017 Planned End Date changed from 30 Jun 2017 to 1 Jun 2019.
- 06 Mar 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.